Pasar al contenido principal

ESTUDIO DEL DETERIORO DE LA ORIENTACION ESPACIAL COMO FACTOR DE RIESGO DE LA ENFERMEDAD DE ALZHEIMER EN PERSONAS MAYORES CON QUEJAS SUBJETIVAS DE MEMORIA.

PID2020-119978RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD PABLO DE OLAVIDE, DE SEVILLA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Impaired glucose metabolism reduces the neuroprotective action of adipocytokines in cognitively normal older adults with insulin resistance

  • López Vilaret, Karel Mauricio
  • Cantero Lorente, José Luis
  • Fernández Álvarez, Marina
  • Calero Lara, Miguel
  • Calero Rueda, Olga
  • Lindín Novo, Mónica
  • Zurrón Ocio, Montserrat
  • Díaz Fernández, Fernando
  • Atienza, Mercedes
Evidence suggests that aging-related dysfunctions of adipose tissue and metabolic disturbances increase the risk of diabetes and metabolic syndrome (MtbS), eventually leading to cognitive impairment and dementia. However, the neuroprotective role of adipocytokines in this process has not been specifically investigated. The present study aims to identify metabolic alterations that may prevent adipocytokines from exerting their neuroprotective action in normal ageing. We hypothesize that neuroprotection may occur under insulin resistance (IR) conditions as long as there are no other metabolic alterations that indirectly impair the action of adipocytokines, such as hyperglycemia. This hypothesis was tested in 239 cognitively normal older adults (149 females) aged 52 to 87 years (67.4 ± 5.9 yr). We assessed whether the homeostasis model assessment-estimated insulin resistance (HOMA-IR) and the presence of different components of MtbS moderated the association of plasma adipocytokines (i.e., adiponectin, leptin and the adiponectin to leptin [Ad/L] ratio) with cognitive functioning and cortical thickness. The results showed that HOMA-IR, circulating triglyceride and glucose levels moderated the neuroprotective effect of adipocytokines. In particular, elevated triglyceride levels reduced the beneficial effect of Ad/L ratio on cognitive functioning in insulin-sensitive individuals; whereas under high IR conditions, it was elevated glucose levels that weakened the association of the Ad/L ratio with cognitive functioning and with cortical thickness of prefrontal regions. Taken together, these findings suggest that the neuroprotective action of adipocytokines is conditioned not only by whether cognitively normal older adults are insulin-sensitive or not, but also by the circulating levels of triglycerides and glucose, respectively
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Plasma and cerebrospinal fluid nonenzymatic protein damage is sustained in Alzheimer's disease

  • Dakterzada, Farida
  • Jové Font, Mariona
  • Cantero, José Luís
  • Pamplona Gras, Reinald
Background Oxidative stress is considered to play an important role in the pathogenesis of Alzheimer's disease (AD). It has been observed that oxidative damage to specific protein targets affecting particular functional networks is one of the mechanisms by which oxidative stress contributes to neuronal failure and consequently loss of cognition and AD progression. Studies are lacking in which oxidative damage is measured at both systemic and central fluid levels and in the same cohort of patients. We aimed to determine the levels of both plasma and cerebrospinal fluid (CSF) nonenzymatic protein damage in patients in the continuum of AD and to evaluate the relation of this damage with clinical progression from mild cognitive impairment (MCI) to AD. Methods Different markers of nonenzymatic post-translational protein modification, mostly from oxidative processes, were detected and quantified in plasma and CSF by isotope dilution gas chromatography‒mass spectrometry using selected ion monitoring (SIM-GC/MS) for 289 subjects: 103 AD, 92 MCI, and 94 control subjects. Characteristics of the study population such as age, sex, Mini-mental state examination, CSF AD biomarkers, and APOE ϵ4, were also considered. Results Forty-seven (52.8%) MCI patients progressed to AD during follow-up (58 ± 12.5 months). After controlling for age, sex, and APOE ϵ4 allele, plasma and CSF concentrations of protein damage markers were not associated with either diagnosis of AD or MCI. The CSF levels of nonenzymatic protein damage markers were associated with none of the CSF AD biomarkers. In addition, neither in CSF nor in plasma were the levels of protein damage associated with the MCI to AD progression. Conclusion The lack of association between both CSF and plasma concentrations of nonenzymatic protein damage markers and AD diagnosis and progression suggests that oxidative damage in AD is a pathogenic mechanism specifically expressed at the cell-tissue level, not in extracellular fluids., This research was supported by the Government of Catalonia, Department of Health (PERIS 2019 SLT008/18/00050), and the Agency for the Management of University and Research Grants (2021SGR 00761) to GPR. The spanish Ministry of Science, Innovation, and Universities (grant RTI2018-099200-B-I00 and PID2022-143140OB-I00), the Diputacio ´ de Lleida (PP10605 - PIRS2021), and the Generalitat of Catalonia: Agency for Management of University and Research Grants (2021SGR00990) and Department of Health (SLT002/16/00250) to RP. The Spanish Ministry of Economy and Competitiveness (PID2020-119978RB-I00), CIBERNED, Alzheimer’s Association (AARG-NTF-22- 924702), the Junta de Andalucía (PY20_00858), and the AndalucíaFEDER Program (UPO-1380913) to JLC. This study has been co-financed by FEDER funds from the European Union (“A way to build Europe”). IRBLleida is a CERCA Programme/Generalitat of Catalonia.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

The shift in the fatty acid composition of the circulating lipidome in Alzheimer's disease

  • Dakterzada, Farida
  • Jové Font, Mariona
  • Cantero, José Luís
  • Mota Martorell, Natàlia
  • Pamplona Gras, Reinald
  • Piñol Ripoll, Gerard
Introduction: Fatty acids (FAs) are the building blocks of complex lipids and signaling compounds; the role of the lipidome fatty acid profile (LFA) in AD progression remains unclear. Methods: The LFA of plasma and cerebrospinal fluid (CSF) samples from 289 participants (103 AD patients, 92 MCI patients, and 94 controls) was determined by GC-FID. The MCI subjects were followed up for 58 ± 12.5 months. Results: In controls, CSF has a more neuroprotective LFA than plasma. In CSF, a higher content of docosahexaenoic acid was associated with a reduced risk of MCI-to-AD progression. In plasma, higher oleic acid content was associated with lower risk of AD, MCI, and MCI-to-AD progression, whereas higher levels of vaccenic acid and docosahexaenoic acid were associated with greater risk of AD and MCI, and higher rate of MCI-to-AD progression, respectively. Discussion: The circulating LFA is involved in the pathogenesis and progression of AD. Highlights: The lipidome fatty acid profile in CSF and plasma was markedly different. Higher levels of vaccenic acid and lower levels of oleic acid in plasma were associated with greater risk of Alzheimer's disease. In plasma, higher levels of oleic acid were associated with a reduced risk of MCI-to-AD progression. Higher levels of docosahexaenoic acid in CSF were associated with a lower risk of MCI-to-AD progression. Higher levels of docosahexaenoic acid in plasma were associated with a greater rate of MCI-to-AD progression., Government of Catalonia,Grant/Award Number:PERIS 2019 SLT008/18/00050; Ministerio de Ciencia, Innovación y Universidades; European Union ’Awaytobuild Europe’, Grant/Award Numbers: RTI2018-099200-B-I00, PID2023-152233OB-I00; Diputació de Lleida, Grant/Award Number: PP10605-PIRS2021; Spanish Ministry of Economy and Competitiveness, Grant/Award Number: PID2020-119978RB-I00; CIBERNED, Alzheimer’s Association, Grant/Award Number:AARG-NTF-22-924702; Junta de Andalucía, Grant/Award Number: PY20_00858; Andalucía-FEDER Program, Grant/Award Number: UPO-1380913; Agency for Management of University and Research Grants, Grant/Award Number: 2021SGR 00761; Agency for Management of University and Research Grants and the European Social Fund, Grant/Award Number: FI_B100153; Agency for Management of University and Research Grants and the European Social Fund, Grant/Award Number: 2021SGR00990
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Human in vivo evidence of associations between herpes simplex virus and cerebral amyloid-beta load in normal aging

  • Cantero, José L.
  • Atienza, Mercedes
  • Sastre, Isabel
  • Bullido, María Jesús
Background: Mounting data suggests that herpes simplex virus type 1 (HSV-1) is involved in the pathogenesis of AD, possibly instigating amyloid-beta (Aβ) accumulation decades before the onset of clinical symptoms. However, human in vivo evidence linking HSV-1 infection to AD pathology is lacking in normal aging, which may contribute to the elucidation of the role of HSV-1 infection as a potential AD risk factor. Methods: To shed light into this question, serum anti-HSV IgG levels were correlated with F-Florbetaben-PET binding to Aβ deposits and blood markers of neurodegeneration (pTau181 and neurofilament light chain) in cognitively normal older adults. Additionally, we investigated whether associations between anti-HSV IgG and AD markers were more evident in APOE4 carriers. Results: We showed that increased anti-HSV IgG levels are associated with higher Aβ load in fronto-temporal regions of cognitively normal older adults. Remarkably, these cortical regions exhibited abnormal patterns of resting state-functional connectivity (rs-FC) only in those individuals showing the highest levels of anti-HSV IgG. We further found that positive relationships between anti-HSV IgG levels and Aβ load, particularly in the anterior cingulate cortex, are moderated by the APOE4 genotype, the strongest genetic risk factor for AD. Importantly, anti-HSV IgG levels were unrelated to either subclinical cognitive deficits or to blood markers of neurodegeneration. Conclusions: All together, these results suggest that HSV infection is selectively related to cortical Aβ deposition in normal aging, supporting the inclusion of cognitively normal older adults in prospective trials of antimicrobial therapy aimed at decreasing the AD risk in the aging population., This work was supported by the Spanish Ministry of Economy and Competitiveness (PID2020-119978RB-I00 to JLC, PID2020-118825GB-I00 to MA and PID2020-113921RB-I00 to MJB), CIBERNED (JLC and MJB), and the Alzheimer’s Association (AARG-NTF-22-924702 to JLC).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cholesterol dysregulation in peripheral blood mononuclear cells of Alzheimer's disease

  • Martín-Montes, A.
  • Recuero, M.
  • Sastre, I.
  • Vilella, E.
  • Rosich-Estragó, M.
  • Atienza, M.
  • Cantero, J.L.
  • Frank-García, A.
  • Bullido, M.J.
Cholesterol and the immune system are involved in Alzheimer's Disease (AD). To investigate the relations among them, we compared the cholesterol content in peripheral blood mononuclear cells (PBMC) of cognitively healthy controls and patients with mild cognitive impairment (MCI) and AD in two independent samples. Free cholesterol content of PBMC was lower in MCI and AD patients, and was modulated by APOE genotype. A decrease of CD8+ and an increase of CD16+ was also found in AD patients. These results suggest that cholesterol levels in PBMCs may represent an early signature of the disease and support the involvement of immune system in AD., This work was supported by the Spanish Ministry of Science and Innovation (PID2020-113921RB-I00 to MJB and AFG, PID2020-119978RB-I00 to JLC, PID2020-118825GB-I00 to MA), CIBERNED (MJB, AFG, JLC, MA), Alzheimer’s Association (AARG-NTF-22-924702 to JLC), the Junta de Andalucía (PY20_00858 to JLC), and the Andalucía-FEDER Program (UPO-1380913 to JLC). Institutional grants from the Fundación Ramón Areces and Banco de Santander to the CBMSO are also acknowledged.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The shift in the fatty acid composition of the circulating lipidome in Alzheimer's disease

  • Dakterzada, Farida
  • Jové Font, Mariona
  • Cantero, José Luís
  • Mota Martorell, Natàlia
  • Pamplona Gras, Reinald
  • Piñol Ripoll, Gerard
Introduction: Fatty acids (FAs) are the building blocks of complex lipids and signaling compounds; the role of the lipidome fatty acid profile (LFA) in AD progression remains unclear. Methods: The LFA of plasma and cerebrospinal fluid (CSF) samples from 289 participants (103 AD patients, 92 MCI patients, and 94 controls) was determined by GC-FID. The MCI subjects were followed up for 58 ± 12.5 months. Results: In controls, CSF has a more neuroprotective LFA than plasma. In CSF, a higher content of docosahexaenoic acid was associated with a reduced risk of MCI-to-AD progression. In plasma, higher oleic acid content was associated with lower risk of AD, MCI, and MCI-to-AD progression, whereas higher levels of vaccenic acid and docosahexaenoic acid were associated with greater risk of AD and MCI, and higher rate of MCI-to-AD progression, respectively. Discussion: The circulating LFA is involved in the pathogenesis and progression of AD. Highlights: The lipidome fatty acid profile in CSF and plasma was markedly different. Higher levels of vaccenic acid and lower levels of oleic acid in plasma were associated with greater risk of Alzheimer's disease. In plasma, higher levels of oleic acid were associated with a reduced risk of MCI-to-AD progression. Higher levels of docosahexaenoic acid in CSF were associated with a lower risk of MCI-to-AD progression. Higher levels of docosahexaenoic acid in plasma were associated with a greater rate of MCI-to-AD progression., Government of Catalonia,Grant/Award Number:PERIS 2019 SLT008/18/00050; Ministerio de Ciencia, Innovación y Universidades; European Union ’Awaytobuild Europe’, Grant/Award Numbers: RTI2018-099200-B-I00, PID2023-152233OB-I00; Diputació de Lleida, Grant/Award Number: PP10605-PIRS2021; Spanish Ministry of Economy and Competitiveness, Grant/Award Number: PID2020-119978RB-I00; CIBERNED, Alzheimer’s Association, Grant/Award Number:AARG-NTF-22-924702; Junta de Andalucía, Grant/Award Number: PY20_00858; Andalucía-FEDER Program, Grant/Award Number: UPO-1380913; Agency for Management of University and Research Grants, Grant/Award Number: 2021SGR 00761; Agency for Management of University and Research Grants and the European Social Fund, Grant/Award Number: FI_B100153; Agency for Management of University and Research Grants and the European Social Fund, Grant/Award Number: 2021SGR00990
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Plasma and cerebrospinal fluid nonenzymatic protein damage is sustained in Alzheimer's disease

  • Dakterzada, Farida
  • Jové Font, Mariona
  • Cantero, José Luís
  • Pamplona Gras, Reinald
Background Oxidative stress is considered to play an important role in the pathogenesis of Alzheimer's disease (AD). It has been observed that oxidative damage to specific protein targets affecting particular functional networks is one of the mechanisms by which oxidative stress contributes to neuronal failure and consequently loss of cognition and AD progression. Studies are lacking in which oxidative damage is measured at both systemic and central fluid levels and in the same cohort of patients. We aimed to determine the levels of both plasma and cerebrospinal fluid (CSF) nonenzymatic protein damage in patients in the continuum of AD and to evaluate the relation of this damage with clinical progression from mild cognitive impairment (MCI) to AD. Methods Different markers of nonenzymatic post-translational protein modification, mostly from oxidative processes, were detected and quantified in plasma and CSF by isotope dilution gas chromatography‒mass spectrometry using selected ion monitoring (SIM-GC/MS) for 289 subjects: 103 AD, 92 MCI, and 94 control subjects. Characteristics of the study population such as age, sex, Mini-mental state examination, CSF AD biomarkers, and APOE ϵ4, were also considered. Results Forty-seven (52.8%) MCI patients progressed to AD during follow-up (58 ± 12.5 months). After controlling for age, sex, and APOE ϵ4 allele, plasma and CSF concentrations of protein damage markers were not associated with either diagnosis of AD or MCI. The CSF levels of nonenzymatic protein damage markers were associated with none of the CSF AD biomarkers. In addition, neither in CSF nor in plasma were the levels of protein damage associated with the MCI to AD progression. Conclusion The lack of association between both CSF and plasma concentrations of nonenzymatic protein damage markers and AD diagnosis and progression suggests that oxidative damage in AD is a pathogenic mechanism specifically expressed at the cell-tissue level, not in extracellular fluids., This research was supported by the Government of Catalonia, Department of Health (PERIS 2019 SLT008/18/00050), and the Agency for the Management of University and Research Grants (2021SGR 00761) to GPR. The spanish Ministry of Science, Innovation, and Universities (grant RTI2018-099200-B-I00 and PID2022-143140OB-I00), the Diputacio ´ de Lleida (PP10605 - PIRS2021), and the Generalitat of Catalonia: Agency for Management of University and Research Grants (2021SGR00990) and Department of Health (SLT002/16/00250) to RP. The Spanish Ministry of Economy and Competitiveness (PID2020-119978RB-I00), CIBERNED, Alzheimer’s Association (AARG-NTF-22- 924702), the Junta de Andalucía (PY20_00858), and the AndalucíaFEDER Program (UPO-1380913) to JLC. This study has been co-financed by FEDER funds from the European Union (“A way to build Europe”). IRBLleida is a CERCA Programme/Generalitat of Catalonia.